Intervention not reported
Withdrawal due to adverse effects · adults with primary hypertension
1 finding from 1 review
Gastrointestinal adverse events · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (general symptoms) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (general symptoms) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects ‐ hepatic toxicity · chronic rhinosinusitis
Systemic antifungal showed no clear difference in adverse effects ‐ hepatic toxicity compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 3.35 [0.14, 78.6]
Studies not reported
Low
Other adverse effects: local irritation · chronic rhinosinusitis
Topical antifungal showed no clear difference in adverse effects ‐ local irritation compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.29 [0.61, 8.62]
Studies not reported
Low
Adverse effects ‐ oestrogen vs PPA · patients with urinary incontinence in post‐menopausal women
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with PUVA therapy (very low certainty).
1 finding from 1 review
Adverse effects (bones and muscles) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).
1 finding from 1 review
Allergic adverse events · chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) showed no clear difference in adverse effects: tardive dyskinesia: long term (+26 weeks) as… compared with MAINTENANCE THERAPY (low certainty).
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes adverse effects: tardive dyskinesia: long term (+ 26 weeks) as… compared with MAINTENANCE THERAPY (very low certainty).
2 findings from 1 review
Adverse events ‐ weight loss · people with drug‐resistant focal epilepsy
Topiramate may leads to higher adverse effects ‐ weight loss/decrease compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse effects (G3/4) outcomes · Women with newly diagnosed epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy
Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).
1 finding from 1 review
Adverse effects of antibiotics: proportion of participants with one or more serious adverse event · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Ciprofloxacin showed no clear difference in adverse effects of antibiotics: proportion of participants with one… compared with placebo added to cycled and culture‐based inhaled tobramycin (TNS)… (moderate certainty).
1 finding from 1 review
Adverse effects (central nervous system) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (central nervous system) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects other than ototoxicity (≥ grade 3 according to NCICTCAEv3 criteria) with intravenous platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review